Liver Fibrosis Clinical Trials
Here are the 6 most popular medical studies for liver fibrosis
SGLT2 Inhibitor
Zibotentan + Dapagliflozin for Liver Cirrhosis
“ I’ve been told my liver was in bad shape . I previously had hep-c and was effectively treated with maverick antiviral treatment which worked But there was a lot of damage done. Would like to get help to fix this condition.”
Procedure
TIPS for Liver Cirrhosis
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
Popular filter options for liver fibrosis trials
Hepatocellular Carcinoma Clinical Trials
View 18 Hepatocellular Carcinoma medical studies.
Biomarker-based Screening
Biomarker Screening with Liver Ultrasound for Liver Cancer
This trial compares ultrasound and biomarker-based methods to screen 5500 people with cirrhosis/hepatitis B for hepatocellular carcinoma. Results assessed after 5.5 years.
Procedure
Suction with Wet Heparin for Cancer
This trial is comparing the amount and quality of tissue obtained by endoscopic ultrasound-guided fine needle biopsy when the device is flushed with an anticoagulant or saline solution, as well as the use of a microsieve.
Liver Cancer Clinical Trials
View 17 Liver Cancer medical studies.
Biomarker-based Screening
Biomarker Screening with Liver Ultrasound for Liver Cancer
This trial compares ultrasound and biomarker-based methods to screen 5500 people with cirrhosis/hepatitis B for hepatocellular carcinoma. Results assessed after 5.5 years.
Procedure
Suction with Wet Heparin for Cancer
This trial is comparing the amount and quality of tissue obtained by endoscopic ultrasound-guided fine needle biopsy when the device is flushed with an anticoagulant or saline solution, as well as the use of a microsieve.
Phase 3 Liver Fibrosis Clinical Trials
View 96 phase 3 liver fibrosis medical studies.
Galectin Inhibitor
Belapectin for Liver Cirrhosis
“ Hep c treated 2016. I have recently been diagnosed with liver disease. I do have liver cirrhosis n I want to really try anything that will at least help me live a lot longer my phone number has changed it's 7209690448.”
Statin
Simvastatin for Liver Cirrhosis
This trial will test whether simvastatin can lower the risk of hepatic decompensation in people with compensated cirrhosis. It will also explore how changes in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.
Plasma Exchange
Plasma Exchange with Human Serum Albumin 5% for Liver Failure
This trial will test whether plasma exchange using human serum albumin 5% can improve outcomes for people with acute-on-chronic liver failure who are at high risk of hospital mortality.
Liver Fibrosis Clinical Trials With No Placebo
View 96 liver fibrosis medical studies that do not have a placebo group.
Biomarker-based Screening
Biomarker Screening with Liver Ultrasound for Liver Cancer
This trial compares ultrasound and biomarker-based methods to screen 5500 people with cirrhosis/hepatitis B for hepatocellular carcinoma. Results assessed after 5.5 years.
Procedure
Suction with Wet Heparin for Cancer
This trial is comparing the amount and quality of tissue obtained by endoscopic ultrasound-guided fine needle biopsy when the device is flushed with an anticoagulant or saline solution, as well as the use of a microsieve.
Behavioural Intervention
Jumpstart Methods for Serious Illness Communication in a Hospital Setting
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
View More Liver Fibrosis Trials
See another 67 many medical studies focused on liver fibrosis.
Frequently Asked Questions
Introduction to liver fibrosis
What are the top hospitals conducting liver fibrosis research?
In the battle against liver fibrosis, top hospitals across different parts of the United States are making significant strides through clinical trials. Located in Edinburg, Texas, the South Texas Research Institute is currently conducting three active trials focused on liver fibrosis. While they may have a smaller number of all-time trials at just three, their first recorded trial in 2020 demonstrates their commitment to exploring new treatments for this condition. Meanwhile, Massachusetts General Hospital in Boston has also dedicated its resources to liver fibrosis research with three ongoing trials and an impressive fifteen completed studies since their initial investigation back in 2000.
On the West Coast, the University of California San Francisco joins the ranks with three active clinical trials targeting liver fibrosis. Although they have conducted fewer all-time trials with a total of seven thus far, their trailblazing journey into understanding this disease began in 2013. Similarly, the University of Alabama at Birmingham is actively engaged in researching liver fibrosis through three ongoing clinical trials and five previously conducted studies since embarking on this path also in 2013.
Adding to these esteemed institutions' efforts is Hunter Holmes McGuire VA Medical Center situated in Richmond. This medical center boasts an extensive history when it comes to studying liver fibrosis; having commenced their first recorded trial as early as 2011 and accumulating an impressive nineteen all-time studies aimed at unraveling potential treatments for this condition.
These hospitals serve as beacons of hope for those affected by liver fibrosis, dedicating themselves to uncovering innovative therapies that can improve patients' lives. Through collaborative efforts nationwide within diverse locations such as Edinburg,Texas,Boston's Massachusetts General Hospital,and centers located from California's San Francisco Bay Area up until Birmingham or Virginia;a united front emerges towards achieving breakthroughs against Liver Fibriosis offering optimism not only for countless individuals directly impacted by this disease but also for shaping future medical advancements that could revolutionize patient care worldwide.
Which are the best cities for liver fibrosis clinical trials?
In the realm of liver fibrosis clinical trials, several cities emerge as prominent hubs for research and advancements. Seattle, Washington; New York, New York; Houston, Texas; Richmond, Virginia; and San Antonio, Texas are leading the way with a significant number of active trials focused on this condition. These trials explore various treatments such as belapectin, Fazirsiran, Atezolizumab, LPCN 1148, Resmetirom, Part B: Treatment Group 3 among others. With their extensive research initiatives and diverse range of investigative approaches to liver fibrosis treatment options these cities provide valuable opportunities for individuals seeking participation in cutting-edge clinical trials that could potentially shape future care strategies.
Which are the top treatments for liver fibrosis being explored in clinical trials?
Liver fibrosis, a serious condition with limited treatment options, is the focus of ongoing clinical trials exploring innovative approaches. One standout contender is prehabilitation, which has shown promise in two active liver fibrosis trials since its introduction in 2021. Another potential breakthrough is the Jumpstart Guide, currently being tested in one trial dedicated to liver fibrosis and first listed in 2023. With researchers diligently working towards new solutions, hope shines on the horizon for patients grappling with this challenging disease.
What are the most recent clinical trials for liver fibrosis?
Recent clinical trials for liver fibrosis offer promising prospects in the field of treatment. Intracavitary tocilizumab has emerged as a potential therapeutic approach, with phase 1 trials demonstrating its efficacy. Similarly, LY3885125 has shown promise in early-phase studies targeting liver fibrosis. Additionally, eHealth mindful movement and breathing group interventions have been explored to alleviate the impact of liver fibrosis on patients' well-being. The advancements made through these clinical trials bring hope to individuals affected by this condition, offering new possibilities for improved care and management strategies in the near future.
What liver fibrosis clinical trials were recently completed?
Several clinical trials focusing on liver fibrosis have recently achieved completion, marking significant progress in the search for effective treatments. In November 2021, Stanford University successfully concluded a trial investigating Empagliflozin 10 MG's potential to address this condition. Similarly, the University of Michigan completed a trial examining the effectiveness of Lactulose during the same month. Back in March 2021, Georgetown University finalized their study evaluating Proglumide's impact on liver fibrosis. These recent developments underscore researchers' commitment to combatting liver fibrosis and offer hope for patients grappling with this challenging condition.